583 related articles for article (PubMed ID: 9793186)
1. Screening for Down's syndrome by fetal nuchal translucency measurement in a high-risk population.
Pajkrt E; Mol BW; van Lith JM; Bleker OP; Bilardo CM
Ultrasound Obstet Gynecol; 1998 Sep; 12(3):156-62. PubMed ID: 9793186
[TBL] [Abstract][Full Text] [Related]
2. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
[TBL] [Abstract][Full Text] [Related]
3. Fetal nuchal translucency screening in 12495 pregnancies in Sardinia.
Zoppi MA; Ibba RM; Floris M; Monni G
Ultrasound Obstet Gynecol; 2001 Dec; 18(6):649-51. PubMed ID: 11844208
[TBL] [Abstract][Full Text] [Related]
4. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome.
Thilaganathan B; Slack A; Wathen NC
Ultrasound Obstet Gynecol; 1997 Oct; 10(4):261-4. PubMed ID: 9383877
[TBL] [Abstract][Full Text] [Related]
5. First trimester nuchal translucency: effective routine screening for Down's syndrome.
Thilaganathan B; Sairam S; Michailidis G; Wathen NC
Br J Radiol; 1999 Oct; 72(862):946-8. PubMed ID: 10673944
[TBL] [Abstract][Full Text] [Related]
6. Screening for chromosomal abnormalities in an unselected population by fetal nuchal translucency.
Hafner E; Schuchter K; Philipp K
Ultrasound Obstet Gynecol; 1995 Nov; 6(5):330-3. PubMed ID: 8590203
[TBL] [Abstract][Full Text] [Related]
7. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
8. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
[TBL] [Abstract][Full Text] [Related]
9. Screening for trisomy 21 by fetal nuchal translucency and maternal age: a multicenter project in Germany, Austria and Switzerland.
Gasiorek-Wiens A; Tercanli S; Kozlowski P; Kossakiewicz A; Minderer S; Meyberg H; Kamin G; Germer U; Bielicki M; Hackelöer BJ; Sarlay D; Kuhn P; Klapp J; Bahlmann F; Pruggmayer M; Schneider KT; Seefried W; Fritzer E; von Kaisenberg CS;
Ultrasound Obstet Gynecol; 2001 Dec; 18(6):645-8. PubMed ID: 11844207
[TBL] [Abstract][Full Text] [Related]
10. Increased nuchal translucency as a marker for fetal chromosomal defects.
Taipale P; Hiilesmaa V; Salonen R; Ylöstalo P
N Engl J Med; 1997 Dec; 337(23):1654-8. PubMed ID: 9385124
[TBL] [Abstract][Full Text] [Related]
11. Natural history of trisomy 21 fetuses with increased nuchal translucency thickness.
Pandya PP; Snijders RJ; Johnson S; Nicolaides KH
Ultrasound Obstet Gynecol; 1995 Jun; 5(6):381-3. PubMed ID: 7552798
[TBL] [Abstract][Full Text] [Related]
12. [Ultrasound screening for Down syndrome and other chromosomal abnormalities by fetal nuchal translucency measurement between 11-14 weeks of gestation].
Dimitrova V; Markov D; Chernev T; Karag'ozova Zh; Mazneĭkova V; Andonova S; Vŭzharova R
Akush Ginekol (Sofiia); 2005; 44(1):32-7. PubMed ID: 15853009
[TBL] [Abstract][Full Text] [Related]
13. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
[TBL] [Abstract][Full Text] [Related]
14. Gestational age standardized nuchal thickness values for estimating mid-trimester Down's syndrome risk.
Bahado-Singh RO; Oz UA; Kovanci E; Deren O; Feather M; Hsu CD; Copel JA; Mahoney MJ
J Matern Fetal Med; 1999; 8(2):37-43. PubMed ID: 10090488
[TBL] [Abstract][Full Text] [Related]
15. The distribution of nuchal translucency at 10-13 weeks of pregnancy.
Schuchter K; Wald N; Hackshaw AK; Hafner E; Liebhart E
Prenat Diagn; 1998 Mar; 18(3):281-6. PubMed ID: 9556045
[TBL] [Abstract][Full Text] [Related]
16. Increased first trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population.
Adekunle O; Gopee A; el-Sayed M; Thilaganathan B
Br J Radiol; 1999 May; 72(857):457-60. PubMed ID: 10505009
[TBL] [Abstract][Full Text] [Related]
17. Measurement of nuchal translucency as a single strategy in trisomy 21 screening: should we use any other marker?
Comas C; Torrents M; Muñoz A; Antolín E; Figueras F; Echevarría M
Obstet Gynecol; 2002 Oct; 100(4):648-54. PubMed ID: 12383528
[TBL] [Abstract][Full Text] [Related]
18. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.
Snijders RJ; Noble P; Sebire N; Souka A; Nicolaides KH
Lancet; 1998 Aug; 352(9125):343-6. PubMed ID: 9717920
[TBL] [Abstract][Full Text] [Related]
19. The implementation of first-trimester scanning at 10-13 weeks' gestation and the measurement of fetal nuchal translucency thickness in two maternity units.
Pandya PP; Goldberg H; Walton B; Riddle A; Shelley S; Snijders RJ; Nicolaides KH
Ultrasound Obstet Gynecol; 1995 Jan; 5(1):20-5. PubMed ID: 7850584
[TBL] [Abstract][Full Text] [Related]
20. [Screening for Down's syndrome at week 10-14 by measuring fetal nuchal translucency thickness].
Maymon R; Dreazen E; Weinraub Z; Bukovsky I; Herman A
Harefuah; 1999 Nov; 137(9):353-7, 432. PubMed ID: 11419032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
